bevantolol

Bevantolol is a cardioselective beta-adrenoceptor antagonist (beta-blocker) primarily used for the treatment of hypertension and angina pectoris. It acts mainly as a selective beta-1 adrenergic receptor antagonist, reducing heart rate and blood pressure by inhibiting the sympathetic effects of epinephrine on the heart. Animal studies indicate that it also exhibits both agonist and antagonist activity at alpha-receptors, though its clinical significance is not fully established. Bevantolol has weak membrane-stabilizing properties and lacks intrinsic sympathomimetic activity[1][2][3]. It has also been investigated for use in glaucoma (as an ophthalmic agent to reduce intraocular pressure) and is under development for Huntington's disease as a vesicular monoamine transporter 2 inhibitor[5][6]. The drug was originally developed by Nippon Chemiphar, with current development activities led by SOM Biotech[6].

Brand names

Calvan

Other names

bevantolol hydrochloride